Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Digital Evaluations and Technologies Enabling Clinical Translation for AD
Authors not listed
Oregon Health and Science University · 2022
Abstract
The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's disease. DETECT-AD uses specialized home-based digital devices (electronic scale, electronic pill box, under-the-mattress sleep sensor, motion activity sensors, wrist watch activity tracker, driving sensor, and computer software) to see if the devices will improve clinical trial assessments. This 36- month-long study will simulate a clinical trial to determine how well the home system detects clinically meaningful changes. Participants in DETECT will receive a brain scan to assess their risk for developing Alzheimer's Disease.
After the scan, homes will be outfitted with the devices\*. Participants will be asked to simply go about their daily routines while data is collected in the background by the digital devices.
The scientists will see if there is a change in the digital assessments in four key areas of life activity:
mobility (walking speed), cognition (computer use), sleep (sleep times), and socialization (time spent out of home). Participants will be asked to take a daily multivitamin as a study 'drug' to mimic clinical trial conditions. Using these methods, the DETECT study will produce outcome measures that reflect real-world everyday function. Establishing the superiority of these novel methods compared to conventional methods (for example, exams in a clinic) will provide a potential new pathway for speeding the development of muchneeded new treatments for Alzheimer's
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2022). Digital Evaluations and Technologies Enabling Clinical Translation for AD. <em>Oregon Health and Science University</em>. https://clinicaltrials.gov/study/NCT05385913
Vancouver
Anonymous. Digital Evaluations and Technologies Enabling Clinical Translation for AD. Oregon Health and Science University. 2022.
BibTeX
@misc{anon2022Digita,
title = {Digital Evaluations and Technologies Enabling Clinical Translation for AD},
author = {Anonymous},
journal = {Oregon Health and Science University},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Istituto Auxologico Italiano 2023
Open access · US-GOV
Avanzamenti in Materia di Screening Cognitivo Telefonico
Universidad de Almeria 2026
Open access · US-GOV
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
University of Washington 2024
Open access · US-GOV
The Impact of Stress and Caregiver Sensitivity on Infant Cellular Aging in a Population of Under-Resourced Families: A Randomized Controlled Trial
Second Affiliated Hospital of Nanchang University 2006
Open access · US-GOV
Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases
Hoffmann-La Roche 2016
Open access · US-GOV
A Pilot Longitudinal Follow-Up Study of Tau Burden in The Brain of Subjects With Alzheimer's Disease Who Previously Participated in Study BP29409 Using [18F]RO6958948 Positron Emission Tomography
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts 2018
Open access · US-GOV